TB-500
Also known as Thymosin Beta-4 fragment, TB4
A synthetic fragment of thymosin beta-4 studied for muscle, tendon, and soft-tissue recovery — frequently stacked with BPC-157.
Evidence grade C · 9 citations · Last reviewed October 2026
- Regulatory status
- Not FDA-approved. In its draft, non-binding policy of October 28, 2026, HHS says it does not intend to bring enforcement action against 503A compounding of TB-500 acetate (Ac-LKKTETQ) given by subcutaneous or intramuscular injection only, when ten stated conditions are met. That is not approval, and no human trial has tested the fragment itself.
- Common routes
- Subcutaneous · intramuscular injection (the only routes the HHS policy covers)
TB-500: the quick answer
- What is TB-500?
- A synthetic seven-amino-acid fragment (Ac-LKKTETQ) of thymosin beta-4, a natural wound-repair protein, sold for injury recovery.
- How strong is the evidence?
- No published human study of the fragment itself. Human data exist only for the full-length protein: phase 1 safety trials and small wound-healing studies.
- US status (as of October 2026)
- Not FDA-approved. Under a draft, non-binding policy, HHS says it does not intend to bring enforcement action against 503A compounding of TB-500 acetate when ten conditions are met, for subcutaneous or intramuscular injection only. Research-chemical vials are outside the policy. Banned in sport under WADA S2.3.
Overview
TB-500 is a synthetic peptide sold online as a research chemical and described as a fragment or equivalent of thymosin beta-4 (Tβ4), a 43-amino-acid protein the body makes naturally and that is present in most nucleated cells, including white blood cells, as well as in platelets. Thymosin beta-4 plays a fundamental role in actin cytoskeleton regulation and is involved in cell migration, wound healing, angiogenesis, and inflammatory modulation. TB-500 is popular in biohacking and athletic recovery communities, where it is frequently stacked with BPC-157 as the so-called Wolverine stack.
A critical distinction that most online sources blur: the thymosin beta-4 studied in formal clinical trials (developed as a pharmaceutical by companies such as RegeneRx Biopharmaceuticals) is a precisely characterized, pharmaceutical-grade protein administered under regulated trial conditions. 'TB-500' as sold by peptide vendors is an unlicensed research chemical with no standardized formulation, no FDA oversight of manufacturing, and no clinical trial conducted under that name. The human evidence that exists (Phase I safety studies and small pilot trials) is for the pharmaceutical Tβ4, not for TB-500.
Evidence grade: C. While thymosin beta-4 has a more developed preclinical and early clinical literature than many research peptides, the gap between the pharmaceutical Tβ4 studied in trials and the TB-500 vials sold online is substantial. No randomized controlled trial has established efficacy for any indication in humans.
Since October 28, 2026, a third source exists alongside the pharmaceutical protein and the research-chemical vial: TB-500 acetate compounded by a licensed 503A pharmacy or physician under the draft, non-binding HHS enforcement-discretion policy, by subcutaneous or intramuscular injection [8]. HHS defines it as the seven-amino-acid fragment Ac-LKKTETQ, molecular weight 949.1. That compounded product is still not FDA-approved, and no human trial has tested the fragment itself.
Regulatory status
FDA has not approved TB-500 for any use. On October 28, 2026, HHS put out a draft enforcement-discretion policy, interim in nature; it is not final, it does not bind HHS or the public, and the comment period closed on November 13, 2026. The open question is whether FDA, through rulemaking, will place TB-500 on the 503A bulk drug substances list. Pending that answer, HHS says it does not intend to bring enforcement action against a licensed physician, a State-licensed pharmacy, or a Federal facility for compounding TB-500 acetate, provided the product meets all ten conditions [8]. HHS repeats in the same document that compounded drugs have no FDA approval and receive no FDA review of safety, effectiveness, or quality.
Route limits: the policy covers TB-500 acetate in subcutaneous or intramuscular injectable forms only [8]. Oral, nasal, topical and intravenous TB-500 fall outside it.
The other conditions: a prescription for a named patient and TB-500 as the single active ingredient, so BPC-157 and TB-500 blends are excluded. The bulk powder traces to an FDA-registered manufacturer and a certificate of analysis that reports identity, purity, potency, endotoxin, heavy metals, microbial limits and impurities. A 510(k)-cleared syringe is the only device allowed in the package, serious adverse events and quality defects get reported to FDA MedWatch and the states [8], and the label carries the sentence "This is a compounded drug product. Not for resale."
History: TB-500 spent September 29, 2023 to April 22, 2026 in FDA's Category 2. CDER argued against listing it, but the Pharmacy Compounding Advisory Committee voted for it [8]. HHS's stated reasons: certificates from FDA-registered manufacturers now supply the identity, assay, impurity, endotoxin, microbial and residual-solvent results CDER found missing; compounding use is now documented; and, in HHS's words, CDER's safety concerns are inferential rather than observed, the parent protein has a controlled human safety record across several routes, and the fragment is rapidly truncated in human serum [8]. That last point is HHS's reasoning, not a published human study of the fragment.
Where to get TB-500
Every telehealth provider we track that offers TB-500. Partners we work with are shown first.
Live Vital
Best for: low-cost, physician-led compounded GLP-1 with peptide and hormone options
Editorial score · methodology
Editorial score · methodology
Pepti
Best for: a low all-in starter price on compounded GLP-1s, with every dose price published up front
Editorial score · methodology
OurView Health
Best for: low, flat compounded GLP-1 pricing at any dose, with no membership fee
Editorial score · methodology
Editorial score · methodology
HuHealth
Best for: choosing your compounding pharmacy, or brand Zepbound and Wegovy at the maker's price plus a $59 care plan
Editorial score · methodology
Enhanced
Best for: prepaying for low-cost compounded GLP-1s with peptides available from one brand
Editorial score · methodology
RxPepsDirect
Best for: Lowest per-vial GLP-1 cost: sema $25, tirz $45, $39 telehealth Rx, 28 states
Editorial score · methodology
Editorial score · methodology
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money
What does TB-500 do? Claims vs evidence
Each row is a claim as it is commonly marketed, the strongest kind of evidence behind it, and what that evidence found. Numbers in brackets point to the sources at the end of this page.
| Claim | Evidence | What the studies found | Sources |
|---|---|---|---|
| Heals wounds and skin faster | No direct evidence | Full-length thymosin beta-4 sped healing in animal wound models, and in a 73-patient placebo-controlled phase 2 trial a topical gel suggested faster venous-ulcer healing at one dose. These studies used the full protein, not the TB-500 fragment. | Sources:[2][6] |
| Speeds muscle and tendon recovery | Animal studies | A 2026 Sports Medicine review covering TB-500 found that unapproved peptides like it show favorable tissue-repair results in animal models while rigorous human data are scarce. No controlled human trial has tested TB-500 for muscle or tendon injury. | Sources:[7] |
| Repairs the heart after a heart attack | No direct evidence | In a 10-patient pilot, patients' own progenitor cells were treated with thymosin beta-4 before transplant, and walking distance and heart function improved more than with untreated cells. The protein was never injected into patients. | Sources:[5] |
| Safe to inject | No direct evidence | Intravenous full-length thymosin beta-4 was well tolerated in two placebo-controlled phase 1 trials in healthy volunteers, with mild or moderate adverse events and none serious. No study has given the TB-500 fragment to people. | Sources:[3][4] |
Evidence levels, strongest first: FDA-approved use, human studies (of any size or design), animal studies, cell studies only, and no direct evidence (nothing tests the claim for this compound).
How it works
Thymosin beta-4's primary mechanism involves sequestering actin monomers (G-actin), which regulates actin polymerization dynamics and enables cell migration. This is fundamental to wound healing: it allows keratinocytes, endothelial cells, and fibroblasts to move into injured tissue and begin repair [1]. In preclinical models, Tβ4 has been shown to promote re-epithelialization, collagen deposition, and new blood vessel formation. It also reduces inflammatory cytokines at wound sites and may support cardiomyocyte survival under ischemic stress.
The actin-sequestering property distinguishes Tβ4 from simple growth factors. It acts upstream of multiple repair pathways simultaneously rather than targeting a single receptor. Research has explored applications in dermal wound healing, corneal repair, cardiac ischemia, and neurological injury [1]. Whether the 'TB-500' sold commercially preserves the full activity of the pharmaceutical Tβ4 protein studied in trials is unknown, as the two have not been directly compared in any published study.
What the evidence says
The most important framing for TB-500 evidence is the distinction between the compound studied in trials and what is sold online. The human data that exist were generated using pharmaceutical thymosin beta-4 under IND (Investigational New Drug) conditions, not with TB-500 research chemicals. A 2010 Phase I study by Ruff et al. administered intravenous Tβ4 to healthy volunteers in single and multiple doses and found the compound was generally well tolerated, establishing a preliminary human safety profile [3]. A 2021 first-in-human Phase I trial of recombinant human Tβ4 in healthy Chinese volunteers confirmed a generally favorable tolerability signal [4]. Neither study evaluated therapeutic efficacy in patients with injury or disease.
The closest thing to therapeutic human evidence comes from a few small studies. Treadwell et al. (2012) reported observations of thymosin beta-4 in dermal wound healing 'in preclinical animal models and in patients,' but this was a case series presented at a conference, not a randomized controlled trial [2]. Guarnera et al. (2010) ran a double-blind, placebo-controlled Phase 2 trial of topical thymosin beta-4 in 73 patients with venous ulcers; safety was comparable to placebo, and the efficacy signal was described as suggestive rather than proven [6]. A pilot cardiac study by Zhu et al. (2016) used Tβ4 to pretreat autologous endothelial progenitor cells before transplantation in acute myocardial infarction patients. This is indirect (Tβ4 was used ex vivo, not injected directly), and the sample was small [5].
An independent 2026 review in Sports Medicine by Mendias and Awan assessed the evidence for unapproved peptide therapies in musculoskeletal injury and athletic performance and concluded that thymosin beta-4 fragments lack the clinical evidence required to support use recommendations in patients or athletes [7]. No completed, peer-reviewed randomized controlled trial has demonstrated efficacy of TB-500 or thymosin beta-4 for muscle recovery, tendon healing, or sports performance. Evidence grade: C.
Typical dosing
No human therapeutic dose has been established for TB-500, and no human study has given the TB-500 fragment at any dose. For context only, the Phase I studies of the full-length protein used intravenous safety protocols in healthy volunteers: single and then 14 daily doses of synthetic thymosin beta-4 at amounts between 42 and 1,260 mg [3], and single doses of 0.05 to 25.0 micrograms per kilogram of recombinant human thymosin beta-4, with 10 daily doses at 0.5 to 5.0 micrograms per kilogram [4]. Those are safety-testing protocols for a different, larger molecule given intravenously, not a dose for subcutaneous TB-500. The weekly milligram figures repeated on vendor sites and forums have no published human basis, so we do not repeat them.
TB-500 is frequently used in combination with BPC-157 in online recovery protocols. Neither compound has been studied in humans as a standalone or combination therapy in a controlled trial, and neither is FDA-approved. The HHS enforcement-discretion policy that covers each one has a single-active-ingredient condition, so a compounded BPC-157 and TB-500 blend falls outside it [8]. The policy sets routes, not doses; if a clinician prescribes compounded TB-500, the dose is their decision.
Safety & side effects
The full thymosin beta-4 protein demonstrated acceptable safety in Phase I trials in healthy adult volunteers [3] [4], but several caveats apply: those trials used pharmaceutical-grade, intravenously administered Tβ4 under controlled clinical supervision, not subcutaneously injected research chemicals of unknown purity. Long-term safety in any human population is unknown, a gap our TB-500 side effects review covers alongside the thymosin beta-4 mix-up. Products sold as TB-500 online are not manufactured under FDA Good Manufacturing Practice (GMP) conditions and may contain incorrect doses, incorrect sequences, degraded peptide, or contaminants.
WADA's 2026 Prohibited List names "Thymosin-β4 and its derivatives e.g. TB-500" under S2.3, growth factors and growth factor modulators, prohibited at all times [9]. TB-500 is a banned substance for athletes in all WADA-governed sports, with or without a prescription. Beyond sports, TB-500 is not FDA-approved for any human indication. Research-chemical vials have no regulatory oversight of manufacturing or purity. A product compounded under the HHS policy must come from a registered manufacturer with a lot-level certificate of analysis and be reported to MedWatch if a serious adverse event occurs [8], which addresses quality but not the missing efficacy and long-term safety data.
Frequently asked questions
What does TB-500 do?
TB-500 is sold as a fragment of thymosin beta-4, a protein that helps repair cells move into injured tissue [2]. The full-length protein sped healing in animal wound models and, as a skin gel, showed possible faster venous-ulcer healing in a 73-patient phase 2 trial [6]. No published study has given the TB-500 fragment to people, and no controlled trial shows that it speeds muscle or tendon recovery [7].
Is TB-500 safe?
The full-length thymosin beta-4 protein was well tolerated in phase 1 intravenous trials in healthy volunteers, with no serious adverse events [3] [4]. Those results do not transfer cleanly to TB-500: no published study has given the fragment to people, and research-chemical vials have no verified identity or purity. Long-term safety is unknown.
TB-500 side effects: what has been reported?
No study reports side effects for TB-500 itself, because none has tested it in people. For the full-length protein, phase 1 trials found adverse events infrequent and mild or moderate, with no dose-limiting toxicity [3] [4], and the topical gel's safety in venous-ulcer patients was comparable to placebo [6].
Is TB-500 the same thing as thymosin beta-4?
TB-500 is commonly described as either the full thymosin beta-4 sequence or a specific fragment of it, depending on the vendor. The key difference is regulatory and quality-related: the thymosin beta-4 studied in formal human trials was a pharmaceutical-grade, precisely characterized product administered under clinical trial conditions. TB-500 sold online is an unlicensed research chemical with no equivalent quality assurance. Human trial data for the pharmaceutical Tβ4 cannot be assumed to apply to TB-500 as sold.
Does TB-500 have human clinical trial evidence?
Not for TB-500 specifically. Human studies exist for pharmaceutical thymosin beta-4, mostly Phase I safety trials in healthy volunteers and a handful of small pilot studies in wound healing and cardiac conditions. None of these trials studied 'TB-500' as a product, and none demonstrated efficacy in a large randomized controlled trial for any indication.
Is TB-500 banned in sports?
Yes. WADA's 2026 Prohibited List names thymosin beta-4 and its derivatives, with TB-500 as the example, under S2.3, prohibited at all times. Athletes in sports with WADA-aligned anti-doping programs can face sanctions for a positive test or admitted use, and a compounded prescription under the HHS policy does not change that.
What is the difference between BPC-157 and TB-500?
Both are unapproved research peptides with primarily preclinical evidence, often used together in online recovery communities. BPC-157 is a gastric peptide fragment with three decades of rat-model data on gut protection and tendon healing, and no human trials. TB-500 is associated with thymosin beta-4, which has a more developed preclinical wound-healing literature and a handful of Phase I human safety trials. Those trials, however, used pharmaceutical Tβ4, not the TB-500 sold online, and tested only safety rather than efficacy. Both carry evidence grade C.
Is TB-500 legal to buy in the United States?
TB-500 is not a federally scheduled substance, and it is not FDA-approved for any indication. In a draft policy from October 28, 2026, HHS says it does not intend to bring enforcement action against licensed 503A pharmacies and physicians that compound TB-500 acetate for one specific patient, as a subcutaneous or intramuscular injection and under ten conditions. Research-chemical TB-500 sold online as not for human consumption is outside that policy, and TB-500 remains banned in WADA-governed sports.
Can TB-500 help with muscle or tendon injuries?
The preclinical biology is mechanistically plausible: thymosin beta-4 promotes cell migration and angiogenesis in animal models of wound healing. But plausible biology is not proven benefit. No controlled human trial has shown that TB-500 or thymosin beta-4 accelerates muscle or tendon healing compared to placebo. Without that evidence, claims of efficacy for injury recovery are extrapolation.
Sources
- [1] Kleinman HK, Sosne G Thymosin β4 Promotes Dermal Healing. Vitam Horm (2016). PMID 27450738
- [2] Treadwell T, Kleinman HK, Crockford D, et al. The regenerative peptide thymosin β4 accelerates the rate of dermal healing in preclinical animal models and in patients. Ann N Y Acad Sci (2012). PMID 23050815
- [3] Ruff D, Crockford D, Girardi G, et al. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci (2010). PMID 20536472
- [4] Wang X, Liu L, Qi L, et al. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers. J Cell Mol Med (2021). PMID 34346165
- [5] Zhu J, Song J, Yu L, et al. Safety and efficacy of autologous thymosin β4 pre-treated endothelial progenitor cell transplantation in patients with acute ST segment elevation myocardial infarction: A pilot study. Cytotherapy (2016). PMID 27288307
- [6] Guarnera G, DeRosa A, Camerini R, et al. The effect of thymosin treatment of venous ulcers. Ann N Y Acad Sci (2010). PMID 20536470
- [7] Mendias CL, Awan TM Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med (2026). PMID 41966639
- [8] US Department of Health and Human Services. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (Appendix A: list; Appendix B: identities, routes, and justifications). HHS (2026). Source
- [9] World Anti-Doping Agency. The 2026 Prohibited List (S0 Non-approved substances; S2.3 Growth factors and growth factor modulators; S4.4 Metabolic modulators). WADA (2026). Source
Further reading
- TB-500 providers Every clinic we confirmed sells single-ingredient TB-500, with the form each one sells. A listing does not confirm the pharmacy meets the policy's conditions.
- How the HHS 503A peptide policy works What the October 2026 policy allows, its ten conditions, and what it leaves out.
- News: HHS draft policy on compounding six peptides Our report on the October 28, 2026 announcement.
- TB-500 side effects and safety What is known, what is not, and the thymosin beta-4 mix-up.
- The KLOW peptide blend A four-peptide blend that includes TB-500 and is not covered by the policy.
- TB-500: the full evidence review Thymosin beta-4 versus the fragment sold as TB-500.
- BPC-157 vs TB-500 The two recovery peptides compared on evidence.
- The BPC-157 and TB-500 stack The HHS policy covers single-ingredient products only.
- Peptide stacking safety What is known about combining peptides.
- MOTS-c Another Appendix A injectable, limited to the same two routes.
- All peptides we cover Evidence grades and regulatory status side by side.
Related peptides
Browse the full peptide directory, see what GLP-1s treat by condition, or compare the best GLP-1 providers.
Educational information only — not medical advice.